Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | MC5R | P33032 | 1/20 | 0.49 |
| ▸ | MC3R | P41968 | 1/20 | 0.49 |
| ▸ | MC1R | Q01726 | 1/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10066223 | 0.96 | REN (0.56) | RENNTSR1AGTR1AGTR2CTSD | |
| SCHEMBL13028249 | 0.95 | REN (0.54) | RENNTSR1AGTR1AGTR2CTSD | |
| SCHEMBL12985531 | 0.95 | REN (0.54) | RENNTSR1AGTR1AGTR2CTSD | |
| SCHEMBL13028816 | 0.88 | TFPI (0.62) | MC4RMC5RMC3RMC1R | |
| SCHEMBL14096140 | 0.81 | RAMP3 (0.60) | MC4RMC5RMC3RMC1R | |
| SCHEMBL29399621 | 0.77 | REN (0.67) | RENAGTR1AGTR2 | |
| SCHEMBL12984358 | 0.77 | MC4R (0.54) | MC4RMC5RMC3RMC1R | |
| SCHEMBL30185029 | 0.76 | NTSR1 (0.45) | NTSR1 | |
| SCHEMBL30974382 | 0.76 | NTSR1 (0.57) | NTSR1 | |
| SCHEMBL30708891 | 0.75 | REN (0.57) | RENAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | BRACCO IMAGING S.P.A. (IT) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | TAGLN2, TTN, TXLNA | REN 2476/4885NTSR1 3820/4885AGTR1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.